In two separate moves, Biohaven seeks to repurpose failed Bristol Myers/Roche Duchenne drug while buying out small biotech

As Biohaven reported its fourth quarter and full-year 2021 earnings to investors, the biotech unveiled two new deals — a licensing deal with a Big Pharma and an acquisition of a smaller company.

Biohaven is in-licensing a Phase III-ready compound for spinal muscular atrophy from Bristol Myers Squibb, the companies...

Click to view original post